Patents Represented by Attorney William Y. Lee

Find this attorney in the Justia Lawyer Directory

  • Heterocyclyls as selective melanin concentrating hormone receptor antagonists for the treatment of obesity and related disorders
    Patent number: 7361769
    Abstract: The present invention discloses compounds of formula I wherein m, n, p, R1, R2 and X, are herein defined, the compounds being novel antagonists for melanin-concentrating hormone (MCH), as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising such MCH antagonists as well as methods of using them to treat obesity, metabolic disorders, eating disorders such as hyperphagia, and diabetes.
    Type: Grant
    Filed: July 14, 2005
    Date of Patent: April 22, 2008
    Assignee: Schering Corporation
    Inventors: Jing Su, Brian A. McKittrick, Haiqun Tang, Thavalakulamgara K. Sasikumar, Li Qiang
  • MCH antagonists for the treatment of obesity
    Patent number: 7348328
    Abstract: The present invention discloses compounds which, are novel antagonists for melanin-concentrating hormone (MCH), as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising such MCH antagonists as well as methods of using them to treat obesity, metabolic disorders, eating disorders such as hyperphagia, and diabetes.
    Type: Grant
    Filed: December 3, 2002
    Date of Patent: March 25, 2008
    Assignee: Schering Corporation
    Inventors: John W. Clader, Anandan Palani, Ruo Xu, Mark D. McBriar, Jing Su, Haiqun Tang
  • MCH antagonists for the treatment of obesity
    Patent number: 7345042
    Abstract: The present invention discloses methods of using antagonists for melanin-concentrating hormone (MCH), to treat obesity, metabolic disorders, eating disorders such as hyperphagia, and diabetes, as well as novel compounds which are antagonists for melanin-concentrating hormone (MCH). In other aspects, the invention is directed to pharmaceutical compositions comprising such MCH antagonists as well as methods for preparing such compounds. Compounds of the invention generally have the structure: where the substituents are as defined herein.
    Type: Grant
    Filed: June 28, 2004
    Date of Patent: March 18, 2008
    Assignee: Schering Corporation
    Inventors: Anandan Palani, Sherry A. Shapiro, Hubert B. Josien, Thomas A. Bara, John W. Clader, Pradeep B. Pushpavanam, Shengjian Li, Mark D. McBriar
  • Neuropeptide Y Y5 receptor antagonists
    Patent number: 7304076
    Abstract: The present invention discloses compounds which, are novel receptor antagonists for NPY Y5 as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising such NPY Y5 receptor antagonists as well as methods of using them to treat obesity, metabolic disorders, eating disorders such as hyperphagia, and diabetes.
    Type: Grant
    Filed: October 24, 2003
    Date of Patent: December 4, 2007
    Assignee: Schering Corporation
    Inventors: Andrew W. Stamford, Ying Huang, Li Guoqing
  • Cannabinoid receptor agonists
    Patent number: 7217732
    Abstract: A compound of the formula or a pharmaceutically acceptable salt thereof, wherein: R1, R2, R3, R4, R5, R6, L1, L2, M, n, p, X, Y and Z are as described in the specification; pharmaceutical compositions thereof, methods of making said pharmaceutical compositions; and methods of use thereof.
    Type: Grant
    Filed: June 17, 2003
    Date of Patent: May 15, 2007
    Assignee: Schering Corporation
    Inventors: Joseph A. Kozlowski, Bandarpalle B. Shankar, Neng-Yang Shih, Ling Tong
  • 2-substituted benzimidazole derivatives as selective melanin concentrating hormone receptor antagonists for the treatment of obesity and related disorders
    Patent number: 7214691
    Abstract: The present invention discloses compounds of formula I wherein Ar, X, R1 and R11 are herein defined, said compounds being novel antagonists for melanin-concentrating hormone (MCH), as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising such MCH antagonists as well as methods of using them to treat obesity, metabolic disorders, eating disorders such as hyperphagia, and diabetes.
    Type: Grant
    Filed: August 23, 2004
    Date of Patent: May 8, 2007
    Assignee: Schering Corporation
    Inventors: Wen-Lian Wu, Duane A. Burnett, Mary Ann Caplen
  • Selective D1/D5 receptor antagonists for the treatment of obesity and CNS disorders
    Patent number: 7211574
    Abstract: The present invention provides compounds, which, are novel antagonists for D1/D5 receptors as well as methods for preparing such compounds. In another embodiment, the invention provides pharmaceutical compositions comprising such D1/D5 receptor antagonists as well as methods of using them to treat CNS disorders, obesity, metabolic disorders, eating disorders such as hyperphagia, and diabetes.
    Type: Grant
    Filed: August 27, 2003
    Date of Patent: May 1, 2007
    Assignee: Schering Corporation
    Inventors: Wen-Lian Wu, Duane A. Burnett, William J. Greenlee, Thavalakulamgara K. Sasikumar
  • Neuropeptide Y Y5 receptor antagonists
    Patent number: 7157472
    Abstract: The present invention discloses compounds which, are receptor antagonists for NPY Y5 as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising such NPY Y5 receptor antagonists as well as methods of using them to treat obesity, metabolic disorders, eating disorders such as hyperphagia, and diabetes.
    Type: Grant
    Filed: June 30, 2003
    Date of Patent: January 2, 2007
    Assignee: Schering Corporation
    Inventors: Andrew W. Stamford, Yusheng Wu
  • Spirosubstituted piperidines as selective melanin concentrating hormone receptor antagonists for the treatment of obesity
    Patent number: 7109207
    Abstract: The present invention discloses compounds which, are novel antagonists for melanin-concentrating hormone (MCH), as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising such MCH antagonists as well as methods of using them to treat obesity, metabolic disorders, eating disorders such as hyperphagia, and diabetes.
    Type: Grant
    Filed: June 26, 2003
    Date of Patent: September 19, 2006
    Assignee: Schering Corporation
    Inventors: Duane A. Burnett, Wen-Lian Wu, Thavalakulamgara K. Sasikumar, Martin S. Domalski
  • Synthesis of temozolomide and analogs
    Patent number: 7087751
    Abstract: This invention relates to a novel process for the synthesis of Temozolomide, an antitumor compound, and analogs, and to intermediates useful in this novel process.
    Type: Grant
    Filed: January 16, 2002
    Date of Patent: August 8, 2006
    Assignee: Schering Corporation
    Inventors: Shen-Chun Kuo, Janet L. Mas, Donald Hou
  • MCH antagonists for the treatment of obesity
    Patent number: 7045636
    Abstract: The present invention discloses compounds, which are novel antagonists for melanin-concentrating hormone (MCH), as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising such MCH antagonists as well as methods of using them to treat obesity, metabolic disorders, eating disorders such as hyperphagia, and diabetes.
    Type: Grant
    Filed: October 23, 2002
    Date of Patent: May 16, 2006
    Assignee: Schering Corporation
    Inventors: Anandan Palani, Sherry A. Shapiro, Mark D. McBriar, Jing Su
  • Aminobenzimidazoles as selective melanin concentrating hormone receptor antagonists for the treatment of obesity and related disorders
    Patent number: 7030113
    Abstract: The present invention discloses compounds of formula I wherein Ar, Z, m, n, p, R1 and R8 are herein defined, said compounds being novel antagonists for melanin-concentrating hormone (MCH), as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising such MCH antagonists as well as methods of using them to treat obesity, metabolic disorders, eating disorders such as hyperphagia, and diabetes.
    Type: Grant
    Filed: September 30, 2004
    Date of Patent: April 18, 2006
    Assignee: Schering Corporation
    Inventors: Thavalakulamgara K. Sasikumar, Duane A. Burnett
  • Heteroaryl urea neuropeptide Y Y5 receptor antagonists
    Patent number: 6982267
    Abstract: The present invention relates to compounds represented by the structural Formula I: or a pharmaceutically acceptable salt thereof, which are useful for the treatment of metabolic and eating disorders such as obesity and hyperphagia, and for the treatment of diabetes and associated disorders.
    Type: Grant
    Filed: December 18, 2001
    Date of Patent: January 3, 2006
    Assignee: Schering Corporation
    Inventors: Andrew Stamford, Youhao Dong, Stuart W. McCombie, Yusheng Wu
  • Heteroaryl urea neuropeptide Y Y5 receptor antagonists
    Patent number: 6946476
    Abstract: The present invention relates to compounds represented by the structural Formula I: or a pharmaceutically acceptable salt thereof, which are useful for the treatment of metabolic and eating disorders such as obesity and hyperphagia, and for the treatment of diabetes and associated disorders.
    Type: Grant
    Filed: June 20, 2002
    Date of Patent: September 20, 2005
    Assignee: Schering Corporation
    Inventors: Andrew Stamford, Youhao Dong, Stuart W. McCombie, Yusheng Wu
  • Substituted urea neuropeptide Y Y5 Receptor antagonists
    Patent number: 6894063
    Abstract: A novel class of compounds such as antagonists of the neuropeptide Y Y5 receptor, methods of making such compounds, pharmaceutical compositions containing one or more such compounds, methods of preparing pharmaceutical formulations comprising one or more such compounds, and methods of treatment, prevention or amelioration of one or more diseases associated with the neuropeptide Y Y5 receptor are disclosed.
    Type: Grant
    Filed: March 12, 2002
    Date of Patent: May 17, 2005
    Assignee: Schering Corporation
    Inventors: William J. Greenlee, Ying Huang, Joseph M. Kelly, Stuart W. McCombie, Andrew W. Stamford, Yusheng Wu
  • Process for synthesis of D1 receptor antagonists
    Patent number: 6875866
    Abstract: In one embodiment, the present invention describes the synthesis of a compound of formula and intermediates therefor.
    Type: Grant
    Filed: February 19, 2003
    Date of Patent: April 5, 2005
    Assignee: Schering Corporation
    Inventors: Vilas H. Dahanukar, Jeffrey M. Eckert, Dinesh Gala, Brian Lucas, Doris P. Schumacher, Ilia Zavialov
  • Synthesis of temozolomide and analogs
    Patent number: 6844434
    Abstract: This invention relates to a novel process for the synthesis of temozolomide, an antitumor compound, and to intermediates useful in this novel process.
    Type: Grant
    Filed: January 16, 2002
    Date of Patent: January 18, 2005
    Assignee: Schering Corporation
    Inventor: Shen-Chun Kuo
  • Muscarinic antagonists
    Patent number: 6831089
    Abstract: The present invention discloses compounds, which are novel muscarinic receptor antagonists, as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising such muscarinic receptor antagonists as well as methods for using them to treat cognitive disorders such as Alzheimer's disease.
    Type: Grant
    Filed: October 8, 2002
    Date of Patent: December 14, 2004
    Assignee: Schering Corporation
    Inventors: Yuguang Wang, Samuel Chackalamannil
  • Nasal spray compositions
    Patent number: 6824762
    Abstract: Aqueous nasal spray compositions comprising a medicament and an aqueous carrier comprising water soluble polymers selected from the group consisting of polyvinylpyrrolidone and mixtures thereof.
    Type: Grant
    Filed: August 28, 2001
    Date of Patent: November 30, 2004
    Assignee: Schering-Plough Healthcare Products Inc.
    Inventors: Joseph A. Haslwanter, William F. Rencher
  • Synthesis of intermediates useful in preparing tricyclic compounds
    Patent number: 6750347
    Abstract: A process is provided for preparing a compound having the formula wherein R is H or Cl.
    Type: Grant
    Filed: June 18, 2002
    Date of Patent: June 15, 2004
    Assignee: Schering-Corporation
    Inventors: Marc Poirier, Yee-Shing Wong, George G. Wu